Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NSPR

InspireMD Inc

Nov 05 • 10:33AM ET

2.16

+0.03 1.56 %

Healthcare • Medical Devices • USA • NASD

Peers: ABT MDT BSX EW SYK ISRG HOLX ZBH AORT NVRO

| Held by: IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	52.43%	Shs Outstand	41.92M	Perf Week	-4.93%
Market Cap	90.05M	Forward P/E	-	EPS next Y	-0.79	Insider Trans	0.47%	Shs Float	19.85M	Perf Month	-10.82%
Enterprise Value	29.02M	PEG	-	EPS next Q	-0.20	Inst Own	37.18%	Short Float	0.58%	Perf Quarter	-9.70%
Income	-46.20M	P/S	11.57	EPS this Y	-13.64%	Inst Trans	11.52%	Short Ratio	1.23	Perf Half Y	-15.36%
Sales	7.78M	P/B	1.41	EPS next Y	10.29%	ROA	-71.65%	Short Interest	0.11M	Perf YTD	-17.94%
Book/sh	1.53	P/C	1.42	EPS next 5Y	6.47%	ROE	-87.61%	52W High	3.80 -43.18%	Perf Year	-12.98%
Cash/sh	1.52	P/FCF	-	EPS past 3/5Y	27.83% 59.73%	ROIC	-69.49%	52W Low	1.99 8.45%	Perf 3Y	91.84%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	15.96% 13.50%	Gross Margin	28.51%	Volatility	9.17% 5.23%	Perf 5Y	-60.43%
Dividend TTM	-	EV/Sales	3.73	EPS Y/Y TTM	-0.78%	Oper. Margin	-602.87%	ATR (14)	0.13	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	6.17	Sales Y/Y TTM	14.04%	Profit Margin	-593.89%	RSI (14)	38.21	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.51	EPS Q/Q	-6.07%	SMA20	-5.76%	Beta	0.69	Target Price	4.50
Payout	-	Debt/Eq	0.04	Sales Q/Q	39.39%	SMA50	-8.82%	Rel Volume	0.53	Prev Close	2.12
Employees	86	LT Debt/Eq	0.04	Earnings	Nov 04 BMO	SMA200	-14.89%	Avg Volume	93.34K	Price	2.16
IPO	Apr 11, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.82% 43.39%	Trades		Volume	11,173	Change	1.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-16	Initiated	Rodman & Renshaw	Buy	$4
Mar-13-15	Downgrade	Oppenheimer	Outperform → Perform
Nov-26-13	Initiated	Oppenheimer	Outperform	$6

Nov-04-25 04:06PM	InspireMD Inc (NSPR) Q3 2025 Earnings Call Highlights: Robust Revenue Growth Amid Rising Expenses (GuruFocus.com) -7.21%
08:15AM	InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	InspireMD Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 05:15PM	Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:30AM	InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer (GlobeNewswire)
06:20PM	Loading…
Oct-21-25 06:20PM	Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates (Zacks)
04:05PM	InspireMD to Announce Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-08-25 08:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-25 04:05PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-21-25 09:06PM	Parkman Healthcare Expands Stake in InspireMD Backing Carotid Innovation (Insider Monkey)
Sep-17-25 08:00AM	InspireMD Announces the Appointment of Dan Dearen to its Board of Directors (GlobeNewswire)
Aug-27-25 09:00AM	InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-05-25 08:00AM	InspireMD Reports Second Quarter 2025 Financial Results (GlobeNewswire) -8.24%
Aug-04-25 10:12AM	What to Expect from InspireMD Inc (NSPR) Q2 2025 Earnings (GuruFocus.com)
08:05AM	RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors (GlobeNewswire)
08:31AM	Loading…
Jul-31-25 08:31AM	InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors (GlobeNewswire) +17.72%
08:30AM	InspireMD Announces Combined Financings of $58 Million (GlobeNewswire)
Jul-22-25 07:00AM	InspireMD to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-17-25 04:58AM	CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains? (Zacks)
Jul-11-25 09:57AM	InspireMD Launches CGuard Prime Carotid Stent System in the U.S. (Zacks)
Jul-09-25 07:00AM	InspireMD Announces U.S. Commercial Launch of CGuard Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire) +7.52%
Jun-24-25 04:05PM	InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of Stroke (GlobeNewswire) -9.49%
Jun-13-25 09:00AM	InspireMD Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke (GlobeNewswire) -7.20%
Jun-03-25 04:05PM	InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer (GlobeNewswire)
May-10-25 03:04AM	InspireMD Inc (NSPR) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com)
May-09-25 08:15AM	InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	InspireMD Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-08-25 05:45PM	Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates (Zacks)
09:49AM	InspireMD Inc (NSPR) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-06-25 08:10AM	IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
09:00AM	Loading…
Apr-30-25 09:00AM	InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference (GlobeNewswire)
Apr-25-25 09:00AM	InspireMD to Announce First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 09:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-25 09:00AM	InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-13-25 03:04AM	InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ... (GuruFocus.com)
Mar-12-25 07:00AM	InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-26-25 08:00AM	InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 08:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.11%
Feb-13-25 07:00AM	InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime 80 cm Carotid Stent System for Use in TCAR procedures (GlobeNewswire)
Feb-04-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.20%
Jan-21-25 07:00AM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Dec-12-24 07:00AM	InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 (GlobeNewswire)
Dec-09-24 07:00AM	InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) (GlobeNewswire)
Nov-25-24 04:05PM	InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors (GlobeNewswire) +10.94%
Nov-13-24 02:09AM	InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... (GuruFocus.com) +5.24%
Nov-12-24 07:00AM	InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:25AM	What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings (GuruFocus.com) +7.68%
Nov-08-24 05:30PM	InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-24 08:00AM	InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th (GlobeNewswire)
Oct-15-24 07:00AM	InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System (GlobeNewswire) -5.66%
Oct-08-24 07:28AM	InspireMD Advances with FDA Study Approval and Global Goals (TipRanks)
Oct-07-24 07:00AM	InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System (GlobeNewswire)
Sep-16-24 07:00AM	InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard Prime Carotid Stent System (GlobeNewswire)
Aug-06-24 08:09AM	InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:00AM	InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment (GlobeNewswire)
Jul-30-24 07:00AM	InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th (GlobeNewswire) -16.87%
Jul-01-24 07:00AM	InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million (GlobeNewswire)
May-28-24 08:53AM	InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 (GlobeNewswire)
May-14-24 10:53AM	NSPR Stock Earnings: InspireMD Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th (GlobeNewswire)
Apr-03-24 08:59AM	InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:00AM	InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 (GlobeNewswire)
Mar-07-24 10:09AM	InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:53PM	NSPR Stock Earnings: InspireMD Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:00AM	InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th (GlobeNewswire)
Feb-12-24 07:00AM	InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard Neuroprotection System (GlobeNewswire)
Feb-05-24 11:27AM	InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS (Zacks)
Jan-31-24 07:00AM	InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework (GlobeNewswire)
Jan-03-24 07:00AM	InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America (GlobeNewswire)
Dec-20-23 07:00AM	InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System (GlobeNewswire) -5.50%
Nov-27-23 07:00AM	InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions (GlobeNewswire) +6.41%
Nov-07-23 09:12AM	InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:11AM	InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ... (GuruFocus.com)
07:00AM	InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 08:00AM	InspireMD to Participate in Upcoming November Investor Conferences (GlobeNewswire) -11.41%
Nov-01-23 02:19PM	InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 (GlobeNewswire) +11.21%
Oct-30-23 09:21AM	InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th (GlobeNewswire) -7.12%
Oct-12-23 07:00AM	InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients (GlobeNewswire) +12.50%
Oct-03-23 07:00AM	InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives (GlobeNewswire)
Aug-31-23 08:00AM	InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 (GlobeNewswire) +5.37%
Aug-08-23 07:00AM	InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-23 08:00AM	InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th (GlobeNewswire)
Jun-26-23 08:00AM	InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial (GlobeNewswire) +7.01%
May-18-23 08:00AM	InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-23 07:00AM	InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.70%
May-15-23 08:00AM	InspireMD Announces Private Placement of Up to $113.6 Million (GlobeNewswire) +26.90%
May-12-23 04:05PM	InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast (GlobeNewswire)
May-05-23 08:00AM	InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update (GlobeNewswire)
May-01-23 08:00AM	InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform (GlobeNewswire) +44.23%
Apr-27-23 08:00AM	InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update (GlobeNewswire)
Mar-30-23 07:00AM	InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update (GlobeNewswire) -7.83%
Mar-20-23 08:00AM	InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer (GlobeNewswire)
Mar-02-23 08:00AM	InspireMD to Report Fourth Quarter and Full-Year 2022 Financial Results on March 30, 2023, and Provide a Corporate Business Update (GlobeNewswire)
Feb-14-23 08:00AM	InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing (GlobeNewswire) +6.23%
Nov-28-22 08:00AM	InspireMD Announces 12 Days of Carotid Stenting Video Series Featuring Fireside Chats with Top Multidisciplinary Vascular Specialists (GlobeNewswire)
Nov-15-22 04:05PM	InspireMD Announces Multiple Presentations Featuring CGuard EPS and its Novel MicroNet Mesh Covering at the 2022 VEITH Symposium (GlobeNewswire) +6.87%
Nov-08-22 07:00AM	InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -14.81%
Oct-25-22 08:00AM	InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update (GlobeNewswire)

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROUBIN GARY S	Director	Jul 30 '25	Buy	2.42	41,322	99,999	608,425	Aug 01 05:00 PM
Kester Thomas J	Director	Jul 30 '25	Buy	2.42	30,991	74,998	420,758	Aug 01 05:00 PM
Slosman Marvin	CEO and President	Jul 30 '25	Buy	2.42	10,330	24,999	2,420,866	Aug 01 05:00 PM
Stuka Paul	Director	Jul 30 '25	Buy	2.42	20,661	50,000	444,195	Aug 01 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NSPR

InspireMD Inc

Upgrade your FINVIZ experience